All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers from Central Drug Research Institute (CDRI) and the Academy of Scientific & Innovative Research (AcSIR) have synthesized and evaluated a series of novel antileishmanial agents. Synthesis and optimization of a series of halogen-rich salicylanilides led to the discovery of compounds [I] and [II], which demonstrated the best antileishmanial activity, with IC50 values of 2.89 μM and 2.09 μM, respectively against Leishmania donovani amastigote.